Gene Patents: Incentive or Impediment for Pharmaceutical Innovation?
Tulane Journal of Technology & Intellectual Property · 08.06.2023 · 24
DOI: 10.37381/ersdsb53 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tulane Journal of Technology & Intellectual Property, online erschienen am 08.06.2023. Verfasst von Yu-Ching Kuo und 1 weiteren Autor:innen.
Abstract (Originalsprache)
This research explores biopharmaceutical companies’ behavior of obtaining patentprotection under the tightened patentability standard for biotechnology innovation. To explore theimportance of innovations, we collected time-series data from twenty firms over two decades andexamined the role of biotechnology on a firm’s operating performance and profit via an empiricalregression model. The results suggest that greater R&D investment brings firms higher revenue andprofit, but a more influential patent does not seem to reward all companies. The possession ofbiotechnology can help companies increase revenue. For large-scale R&D firms, marketinginvolvement is particularly important to boost revenue, but low-scale R&D firms should avoidhaving a high ratio of biotechnology in their patent portfolio strategy.
Zitieren
APA
Kuo, Y., & Ho, M. H. (2023). Gene Patents: Incentive or Impediment for Pharmaceutical Innovation?. Tulane Journal of Technology & Intellectual Property, 24. https://doi.org/10.37381/ersdsb53
Vancouver
Kuo Y, Ho MH. Gene Patents: Incentive or Impediment for Pharmaceutical Innovation?. Tulane Journal of Technology & Intellectual Property. 2023;24. doi:10.37381/ersdsb53
BibTeX
@article{Kuo2023,
author = {Kuo, Yu-Ching and Ho, Mei Hsiu-Ching},
title = {Gene Patents: Incentive or Impediment for Pharmaceutical Innovation?},
journal = {Tulane Journal of Technology & Intellectual Property},
year = {2023},
volume = {24},
doi = {10.37381/ersdsb53}
}
EUVIMED